Aurobindo Pharma Ltd
NSE: AUROPHARMA BSE: 524804
₹1705
+10.50 (0.62%)
Fri, 06 Nov 2026, 10:01 pm
Market Cap (in Cr)97756.7
PE Ratio26.64
Dividend0.24
Health Technology
Pharmaceuticals: Other
24.5KAurobindo Pharma Ltd Company History
1986
- Incorporated on 26 December as Private Limited company.
- Registered with Registrar of Companies, Andhra Pradesh at Hyderabad.
- Chief promoters: P.V. Ramaprasad Reddy and K. Nityananda Reddy.
1992
- Converted to Public Limited company effective 30 April.
- Issued bonus shares in 1:1 ratio in May.
- Set up unit for CMIC Chloride at Pashamylaram through Chaitanya Organics Pvt. Ltd.
1993
- Issued bonus shares in 2:1 ratio in June.
- Set up bulk drug unit at Bollaram.
- Set up formulations unit at Kukatpally.
- Planning bulk drug cum formulations plant for sterile products.
1994
- Issued bonus shares in 7:20 ratio in November.
- Increased Pondicherry unit capacity from 204 TPA to 300 TPA.
- Bollaram unit for Cloxacillin and Dicloxacillin manufacture.
- Upgraded plant capacity from 78 TPA to 84 TPA; set up block for Astemizole, Domperidone, Famotidine, Omeprazole (9 TPA).
- Kukatpally formulations unit capacity: 360 million tablets, 480 million capsules per annum.
- Increased Chaitanya Organics capacity from 120 TPA to 144 TPA; started DCMIC Chloride; new block for Norfloxacin, Pefloxacin (60 TPA).
- Amalgamated with Chaitanya Organics Pvt. Ltd. effective 1 April; took over assets and liabilities.
- Issued one equity share for each Chaitanya Organics share per amalgamation scheme.
- Entered domestic formulations market in 5 states.
- Set up marketing agencies in Sri Lanka, Thailand, Russia, Nigeria; planned offices in Hong Kong, Moscow, Nigeria.
1995
- Videocon International and Videocon Appliances sold Aurobindo shares at Rs 180 premium in January.
1997
- Negotiating alliance with Glaxo India for bulk drug supply.
- Annual capacities: 300 million capsules and 840 tonnes bulk drugs.
- Proposed manufacture of fourth generation cephalosporins.
1998
- Setting up wholly-owned subsidiaries in US and Hong Kong.
- Obtained shareholder permission to invest $200,000 in Aurobindo Pharma (Miami) Inc and $150,000 in Aurobindo Pharma (Hong Kong) Pte Ltd.
- Launched Auronim Suspension in paediatric segment.
1999
- Received BIFR in-principle approval to buy plant.
- Allotted 551,000 equity shares at premium of Rs 480 by private placement.
- Planned joint ventures in Brazil and China.
2000
- Proposed two joint ventures in US for cephalosporins and non-cephalosporins.
- Setting up two JVs for formulations in US with $12 million investment.
- Amalgamated with Sri Chakra Remedies Limited.
2001
- Launched Immunus anti-viral division.
- Restructured management: P V Ramaprasad Reddy appointed executive chairman, K Nityananda Reddy appointed managing director.
- Launched Efavirenz (Viranz) and Nelfinavir (NELVEX) for AIDS treatment.
2002
- Directors Srinivas Lanka, A J Kamath, and A Siva Rama Prasad stepped down; Lanka reappointed as non-executive independent director.
- Planned to allot further equity shares/warrants to promoters.
- Sathyamurthy appointed as Additional Director.
2003
- Appointed Dr. K A Balasubramanian as additional independent director.
- Citadel Aurobindo Biotech JV launched Aztreonam (TREONAM).
- Set up Aurobindo Tongling (Datong) pharmaceuticals JV in China.
- Infused Rs 59 crore in Aurobindo (Datong) Pharma for Pen G manufacture.
- Launched second JV in US for R&D with Salus Pharmaceuticals.
- Allotted 950,000 equity shares upon conversion of warrants.
- Filed 20 patents and obtained 2 in US.
- UTI sold 3% stake.
- Approved preferential issue of up to 3,100,000 equity shares.
- Allotted 3,100,000 equity shares to Merlion India Fund.
2004
- P. Suneela Rani sold 680,000 equity shares.
- Received first Certificate of Suitability (CoS) from EDQM for gastroenterology product.
- EGM approved preferential allotment of equity shares.
- Delisted securities from Ahmedabad Stock Exchange effective January 15.
2005
- USFDA approved Unit VIII facility for APIs for US market.
- AIDS drug received USFDA clearance.
- Received EDQM approval for Flucloxacillin Sodium.
- Received USFDA approval for Sertraline Hydrochloride Tablets.
- Received USFDA approval for Cephalexin Capsules.
- Received final USFDA approval for Mirtazapine Orally Disintegrating Tablets.
2006
- Received final USFDA approval for Mirtazapine ODT 45mg.
- Received USFDA tentative approval for Simvastatin Tablets.
- Received USFDA approval for Didanosine Chewable Tablets.
- Received MEB Netherlands approval for Mirtazapine ODT.
- Appointed A. Mohan Rami Reddy as Company Secretary.
- Received final USFDA approval for Simvastatin tablets.
- Arm acquired Dutch firm Pharmacin.
2007
- Received USFDA approval for Cefadroxil capsules 500 mg.
- Unveiled new logo and corporate identity.
2008
- Received USFDA approval for Cefdinir 300mg Capsules.
- Appointed K Raghunathan as Additional Director.
- Awarded ARV contract worth Rs 70 crores by NACO.
- Received final USFDA clearance for Didanosine Delayed Release capsules.
2009
- Received Swissmedic approvals for Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets.
2010
- Received final USFDA approval for Ceftazidime injection.
2011
- Received USFDA tentative approval for Famciclovir Tablets.
- Announced strategic divestment of Aurobindo (Datong) Bio Pharma, China.
- Received USFDA tentative approval for Levofloxacin Tablets.
- Received USFDA tentative approval for Venlafaxine Extended Release Capsules.
- Received Platinum Certificate of Outstanding Exports Award from Pharmexcil.
- Split face value of shares from Rs 5 to Re 1.
2012
- Received final USFDA approval for Quetiapine Fumarate Tablets.
- Received final USFDA approval for Olanzapine Tablets.
- Received USFDA approval for Lamivudine and Zidovudine anti-HIV drugs.
- Received USFDA approval for Clopidogrel tablets.
- Received final USFDA approval for Metformin Hydrochloride Extended Release Tablets.
2013
- Received USFDA approval for anti-migraine tablets.
- Received USFDA tentative approval for Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets.
- Received final USFDA approval for Cefadroxil oral suspension.
- Received final USFDA approval for Rizatriptan Benzoate ODT.
2014
- Completed acquisition of Natrol.
- Received USFDA approval for Amoxicillin for Oral Suspension.
- Completed acquisition of select Western European businesses of Actavis.
- Received USFDA approval for Divalproex Sodium Extended-Release Tablets.
- Received USFDA approval for Repaglinide Tablets.
2015
- Received USFDA approval for Valsartan Tablets USP.
- Received USFDA approval for Lacosamide Tablets.
- Received USFDA approval for Sildenafil injection.
- Received USFDA approval for Atracurium Besylate injections.
- Received USFDA approval for Cefixime for Oral Suspension USP.
- Received USFDA approval for Famotidine Tablets.
- Allotted bonus shares in 1:1 ratio.
2016
- Received USFDA approval for Norethindrone Acetate Tablets.
- Received USFDA approval for Tranexamic Acid Injection.
- Received USFDA approval for Voriconazole Tablets.
- Received USFDA approval for Celecoxib Capsules.
- Received USFDA approval for Acetylcysteine Injection.
- Received USFDA approval for Naproxen Tablets.
- Received USFDA approval for Pantoprazole Sodium for Injection.
- Received USFDA approval for Amlodipine & Valsartan Tablets.
- Received USFDA approval for Hydromorphone Hydrochloride Tablets.
2017
- Received USFDA approval for Levetiracetam in Sodium Chloride Injection.
- European subsidiary signed agreement to acquire Generis Farmaceutica SA in Portugal.
- Acquired four biosimilars products from TL Biopharmaceutical AG.
- Received USFDA approval for Atomoxetine Capsules.
2018
- Received USFDA approval for Omeprazole tablets.
- Received USFDA approval for Ertapenem Injection.
- Signed pact to acquire certain assets from Sandoz.
- Arm signed JV pact with Shandong Luoxin in China.
2019
- Completed acquisition of Apotex and businesses in five European countries.
- Completed acquisition of marketed portfolio from Spectrum Pharmaceuticals.
- Introduced Cinacalcet Hydrochloride Tablets in US market.
2020
- Tied up with BIRAC to develop COVID-19 vaccine.
- Collaborated with CSIR to develop COVID-19 vaccine.
- Signed exclusive licensing agreement with COVAXX.
2021
- Received USFDA approval for Droxidopa Capsules.
- Received NCLT approval for scheme of amalgamation.
2022
- Acquired 51% stake in GLS Pharma Limited.
- Arm received final USFDA approval for Vasopressin injection.
- Arm received USFDA approval for Triamcinolone Acetonide injectable suspension.
2023
- Arm received USFDA approval for cancer drug.
- To launch HIV triple combination product for children under ViiV Healthcare licence.
2024
- Received first USFDA approval for Lidocaine Hydrochloride Injection.
- Commissioned four plants in Andhra Pradesh including Pen-G facility.
